Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AGIO Agios Pharmaceuticals	$36.68 +0.2%	$36.38	$23.42 ▼ $62.58	$2.13B	0.8	712,425 shs	242,800 shs
BCYC Bicycle Therapeutics	$7.38 +0.4%	$7.90	$6.10 ▼ $28.67	$511.07M	1.44	322,882 shs	543,730 shs
BEAM Beam Therapeutics	$17.63 +0.6%	$18.87	$13.52 ▼ $35.25	$1.78B	2.22	2.07 million shs	3.59 million shs
XENE Xenon Pharmaceuticals	$37.95 +0.7%	$32.31	$26.74 ▼ $46.00	$2.93B	1.16	897,788 shs	614,590 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AGIO Agios Pharmaceuticals	+3.48%	-2.94%	-6.68%	+29.55%	-18.84%
BCYC Bicycle Therapeutics	+1.80%	-2.78%	-9.03%	-9.48%	-67.17%
BEAM Beam Therapeutics	+3.91%	-4.26%	-17.24%	+1.57%	-28.02%
XENE Xenon Pharmaceuticals	+4.67%	+9.92%	+15.55%	+27.39%	-2.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AGIO Agios Pharmaceuticals	4.3777 of 5 stars	3.4	2.0	4.3	3.3	0.8	1.9
BCYC Bicycle Therapeutics	3.449 of 5 stars	3.4	4.0	0.0	2.1	4.2	0.6
BEAM Beam Therapeutics	2.2605 of 5 stars	3.5	0.0	0.0	2.9	2.5	0.6
XENE Xenon Pharmaceuticals	1.9919 of 5 stars	3.5	1.0	0.0	2.4	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AGIO Agios Pharmaceuticals	2.75	Moderate Buy	$56.33	53.58% Upside
BCYC Bicycle Therapeutics	2.70	Moderate Buy	$22.22	201.11% Upside
BEAM Beam Therapeutics	3.07	Buy	$48.45	174.84% Upside
XENE Xenon Pharmaceuticals	3.00	Buy	$53.20	40.18% Upside

Current Analyst Ratings Breakdown

Latest BCYC, XENE, AGIO, and BEAM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	BCYC Bicycle Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Market Outperform ➝ Market Outperform	$22.00 ➝ $10.00
8/12/2025	BCYC Bicycle Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$17.00 ➝ $13.00
8/12/2025	XENE Xenon Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$55.00
8/12/2025	XENE Xenon Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$57.00 ➝ $55.00
8/12/2025	XENE Xenon Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$42.00 ➝ $43.00
8/11/2025	BCYC Bicycle Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$27.00
8/11/2025	BCYC Bicycle Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$48.00 ➝ $44.00
8/6/2025	BEAM Beam Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$25.00 ➝ $21.00
7/28/2025	AGIO Agios Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Outperform ➝ Sector Outperform	$71.00 ➝ $65.00
7/22/2025	AGIO Agios Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$52.00 ➝ $51.00
7/21/2025	BEAM Beam Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AGIO Agios Pharmaceuticals	$36.50M	58.39	N/A	N/A	$23.57 per share	1.56
BCYC Bicycle Therapeutics	$35.28M	14.49	N/A	N/A	$9.66 per share	0.76
BEAM Beam Therapeutics	$63.52M	28.08	N/A	N/A	$10.35 per share	1.70
XENE Xenon Pharmaceuticals	$9.43M	310.32	N/A	N/A	$8.22 per share	4.62

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AGIO Agios Pharmaceuticals	$673.72M	$11.00	3.33	N/A	N/A	1,590.42%	-3.49%	-3.23%	10/30/2025 (Estimated)
BCYC Bicycle Therapeutics	-$169.03M	-$3.51	N/A	N/A	N/A	-1,257.00%	-32.43%	-26.80%	10/30/2025 (Estimated)
BEAM Beam Therapeutics	-$376.74M	-$4.50	N/A	N/A	N/A	-661.31%	-43.15%	-31.06%	N/A
XENE Xenon Pharmaceuticals	-$234.33M	-$3.55	N/A	N/A	N/A	N/A	-38.50%	-36.47%	N/A

Latest BCYC, XENE, AGIO, and BEAM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	XENE Xenon Pharmaceuticals	-$1.03	-$1.07	-$0.04	-$1.07	N/A	N/A
8/8/2025	Q2 2025	BCYC Bicycle Therapeutics	-$0.95	-$1.14	-$0.19	-$1.14	$9.43 million	$2.90 million
8/5/2025	Q2 2025	BEAM Beam Therapeutics	-$1.04	-$1.00	+$0.04	-$1.00	$13.29 million	$8.47 million
7/31/2025	Q2 2025	AGIO Agios Pharmaceuticals	-$1.74	-$1.93	-$0.19	-$1.93	$9.46 million	$12.50 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AGIO Agios Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BCYC Bicycle Therapeutics	N/A	N/A	N/A	N/A	N/A
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AGIO Agios Pharmaceuticals	N/A	14.48	14.04
BCYC Bicycle Therapeutics	N/A	10.39	14.86
BEAM Beam Therapeutics	N/A	6.75	6.75
XENE Xenon Pharmaceuticals	N/A	15.14	17.66

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AGIO Agios Pharmaceuticals	N/A
BCYC Bicycle Therapeutics	86.15%
BEAM Beam Therapeutics	99.68%
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
AGIO Agios Pharmaceuticals	4.30%
BCYC Bicycle Therapeutics	22.90%
BEAM Beam Therapeutics	3.50%
XENE Xenon Pharmaceuticals	4.07%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AGIO Agios Pharmaceuticals	390	58.10 million	55.60 million	Optionable
BCYC Bicycle Therapeutics	240	69.25 million	53.40 million	Optionable
BEAM Beam Therapeutics	510	101.16 million	97.62 million	Optionable
XENE Xenon Pharmaceuticals	210	77.11 million	73.61 million	Optionable

BCYC, XENE, AGIO, and BEAM Headlines

Recent News About These Companies

Chardan Capital Reiterates Buy Rating for Xenon Pharmaceuticals (NASDAQ:XENE)

August 14 at 2:13 AM | americanbankingnews.com

Xenon Pharmaceuticals (NASDAQ:XENE) Shares Gap Up After Analyst Upgrade

August 13 at 10:52 AM | marketbeat.com

Royal Bank Of Canada Has Lowered Expectations for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price

August 13 at 10:25 AM | marketbeat.com

Xenon Pharmaceuticals (NASDAQ:XENE) Given New $43.00 Price Target at Wedbush

August 13 at 9:40 AM | marketbeat.com

Wedbush Issues Positive Forecast for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price

August 13 at 3:31 AM | americanbankingnews.com

TD Cowen Reaffirms Their Buy Rating on Xenon (XENE)

August 13 at 2:39 AM | theglobeandmail.com

Xenon Completes Patient Recruitment for Phase 3 Study

August 13 at 2:39 AM | theglobeandmail.com

Xenon Pharmaceuticals (NASDAQ:XENE) Announces Quarterly Earnings Results

August 12 at 9:25 PM | marketbeat.com

Xenon Pharmaceuticals price target lowered to $55 from $57 at RBC Capital

August 12 at 8:39 PM | msn.com

Xenon Pharmaceuticals: Pushing Azetukalner Towards Finish Line With Phase 3 2026 Data Release

August 12 at 3:05 PM | seekingalpha.com

Xenon Q2 Loss Wider Than Expected, Pipeline Development in Focus

August 12 at 11:21 AM | zacks.com

Xenon Pharmaceuticals Reports Q2 2025 Progress and Outlook

August 12 at 3:55 AM | msn.com

Xenon Pharmaceuticals Inc. (XENE) Q2 2025 Earnings Call Transcript

August 11 at 12:03 AM | seekingalpha.com

Xenon Pharmaceuticals: Q2 Earnings Snapshot

August 11 at 10:54 PM | chron.com

Xenon Pharmaceuticals jumps after massive earnings beat

August 11 at 5:54 PM | investing.com

Xenon Reports Second Quarter 2025 Financial Results & Business Update

August 11 at 4:01 PM | globenewswire.com

Mutual of America Capital Management LLC Acquires Shares of 48,763 Xenon Pharmaceuticals Inc. (NASDAQ:XENE)

August 11 at 4:51 AM | marketbeat.com

Xenon Pharma Q2 2025 Earnings Preview

August 11 at 2:52 AM | seekingalpha.com

2XENE : A Look Ahead: Xenon Pharmaceuticals's Earnings Forecast

August 8, 2025 | benzinga.com

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives $54.82 Consensus PT from Brokerages

August 7, 2025 | americanbankingnews.com

Xenon Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:XENE)

August 7, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCYC, XENE, AGIO, and BEAM Company Descriptions

Agios Pharmaceuticals NASDAQ:AGIO

$36.68 +0.07 (+0.19%)

Closing price 04:00 PM Eastern

Extended Trading

$36.40 -0.28 (-0.78%)

As of 04:20 PM Eastern

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Bicycle Therapeutics NASDAQ:BCYC

$7.38 +0.03 (+0.41%)

Closing price 04:00 PM Eastern

Extended Trading

$7.37 -0.01 (-0.14%)

As of 04:10 PM Eastern

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

Beam Therapeutics NASDAQ:BEAM

$17.63 +0.11 (+0.63%)

Closing price 04:00 PM Eastern

Extended Trading

$17.66 +0.04 (+0.20%)

As of 04:21 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Xenon Pharmaceuticals NASDAQ:XENE

$37.95 +0.28 (+0.74%)

Closing price 03:59 PM Eastern

Extended Trading

$37.96 +0.00 (+0.01%)

As of 04:20 PM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time